Pfizer Inc. (NYSE:PFE) Reported Unsatisfactory Results Of Drug For Psoriasis Treatment

Boston, MA 10/18/2013 (wallstreetpr) – A drug tofacitinib which the drug maker Pfizer Inc. (NYSE:PFE) had earlier come up with to treat psoriasis is now seen to demonstrate mixed results in the trials. The company reported that the drug has shown non-inferiority compared to Enbrel in treating psoriasis in adults who were suffering moderately or severely from the disease, but only when patients are induced with high doses of the drug. The results were significant at a late stage study. However, contrasting results were seen when the patients were treated with lesser doses of the drug tofacitinib. Tofacitinib did not meet the non-inferiority criteria to high-dose Enbrel at the 5 mg BID dose.

The drug maker had carried out a 12 week study which they had named OPT Compare. Reportedly, more than around 7 million people are suffering from this disease in America. In the study, they administered 5mg and 10mg of the drug to patients two times every day. The drug was given orally and compared against placebo. At the same time, they also observed the results of the approved injectable drug Enbrel as per the established norm of starting dose of two doses per week. The effectiveness in both the cases was then observed.

An analyst of the SI Group concluded that the 10mg dose of the drug tofacitinib produces results of similar effectiveness as those produced by Enbrel, only the latter are high cost biotech drugs which are grown inside living cells. The restriction of the 10mg tofacitinib that he noted was the increased risk factor due to high doses over the 5mg dose of the drug, which in turn is less effective.

Please make sure to read and completely understand our disclaimer at While reading this article one must assume that we may be compensated for posting this content on our website.

Published by Chris Brown

About Me: I have a Phd in Economics Gender: Male Interests: Playing games like cricket, volleyball Favorite Music: hip hop, rock, jazz

Recent Stories

SignUp Now For Our Featured Newsletter